Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 5, 2014, Pages 1397-1406

  Marra, Fawziah ^a   Chong, Mei ^b   Henry, Bonnie ^a,b   Patrick, David M ^a,b   Kendall, Perry ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c MINISTRY OF HEALTH   (Canada)

Author keywords

Antivirals; Cohort; Mortality; Oseltamivir; Population based; Zanamivir

Indexed keywords

SIALIDASE INHIBITOR; ANTIVIRUS AGENT; OSELTAMIVIR; SIALIDASE; ZANAMIVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CHILD; COHORT ANALYSIS; COMORBIDITY; DRUG EFFICACY; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PANDEMIC; PANDEMIC INFLUENZA; POPULATION RESEARCH; PRESCRIPTION; PROPENSITY SCORE; RETROSPECTIVE STUDY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INFANT; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BRITISH COLUMBIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEURAMINIDASE; OSELTAMIVIR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT; ZANAMIVIR;

EID: 84898488683     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt496     Document Type: Article

References (43)

1. Outbreak of swine-origin influenza A (H1N1) virus infection-Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 467-70.
2. Lessler J, Reich NG, Cummings DA et al. Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school. N Engl J Med 2009; 361: 2628-36.
3. Swine influenza A (H1N1) infection in two children-southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 400-2.
4. Update: infections with a swine-origin influenza A (H1N1) virus-United States and other countries, April 28, 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 431-3.
5. Khan K, Arino J, HuWet al. Spread of a novel influenza A (H1N1) virus via global airline transportation. N Engl J Med 2009; 361: 212-4.
6. Kumar A, Zarychanski R, Pinto R et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302: 1872-9.
7. BCCentreforDiseaseControl.BCInfluenzaSurveillanceBulletins:2009-2010. http://www.bccdc.ca/dis-cond/DiseaseStatsReports/influSurveillanceReports. htm (13 April 2013, date last accessed).
8. Ministry of Health. BC's Response to the H1N1 Pandemic: A Summary Report, June 2010. http://www.health.gov.bc.ca/pho/pdf/PHO_Report_BC_ Response_to_the_H1N1_Pandemic_June2010.pdf (13 April 2013, date last accessed).
9. Skowronski DM, Janjua NZ, De Serres G et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 2011; 342: c7297.
10. Rosenbaum PR. Observational Studies, 2nd edn. New York: Springer-Verlag, 2002.
11. Quan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-9.
12. Hiba V, Chowers M, Levi-Vinograd I et al. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): a retrospective cohort study. J Antimicrob Chemother 2011; 66: 1150-5.
13. Yates L, Pierce M, Stephens S et al. Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant. Health Technol Assess 2010; 14: 109-82.
14. Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361: 1935-44.
15. Jamieson DJ, Honein MA, Rasmussen SA et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009; 374: 451-8.
16. Creanga AA, Johnson TF, Graitcer SB et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol 2010; 115: 717-26.
17. Gerardin P, El Amrani R, Cyrille B et al. Low clinical burden of 2009 pandemic influenza A (H1N1) infection during pregnancy on the island of La Reunion. PLoS One 2010; 5: e10896.
18. Siston AM, Rasmussen SA, Honein MA et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303: 1517-25.
19. Gilca R,DeSerres G, BoulianneNet al. Risk factors for hospitalization and severe outcomes of the 2009pandemicH1N1influenza inQuebec, Canada. Influenza Other Respir Viruses 2011; 5: 247-55.
20. Louie JK, Acosta M, Jamieson DJ et al. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 2010; 362: 27-35.
21. ANZIC Influenza Investigators and Australasian Maternity Outcomes Surveillance System. Critical illness due to 2009 A/H1N1 influenza in pregnant and postpartum women: population based cohort study. BMJ 2010; 340: c1279.
22. WHO. Influenza Updates. http://www.who.int/influenza/surveillance_ monitoring/updates/en/ (19 November 2013, date last accessed).
23. Hurt AC, Chotpitayasunondh T, Cox NJ et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012; 12: 240-8.
24. Hayden FG, Osterhaus AD, Treanor JJ et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337: 874-80.
25. Monto AS, Fleming DM, Henry D et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-61.
26. Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000; 355: 1845-50.
27. Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283: 1016-24.
28. Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20: 127-33.
29. Makela MJ, Pauksens K, Rostila Tet al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 2000; 40: 42-8.
30. Lalezari J, Campion K, Keene O et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001; 161: 212-7.
31. Aoki FY, Macleod MD, Paggiaro P et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51: 123-9.
32. Cooper NJ, Sutton AJ, Abrams KR et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326: 1235.
33. Kaiser L, Wat C, Mills T et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163: 1667-72.
34. Van Kerkhove MD, Vandemaele KA, Shinde Vet al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011; 8: e1001053.
35. Skarbinski J, Jain S, Bramley A et al. Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States- September-October 2009. Clin Infect Dis 2011; 52 Suppl 1: S50-9.
36. Louie JK, Acosta M, Winter K et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302: 1896-902.
37. Libster R, Bugna J, Coviello S et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med 2010; 362: 45-55.
38. JouvetP,HutchisonJ,PintoRetal.Critical illness inchildrenwithinfluenza A/pH1N1 2009 infection in Canada. Pediatr Crit Care Med 2010; 11: 603-9.
39. Lister P, Reynolds F, Parslow R et al. Swine-origin influenza virus H1N1, seasonal influenza virus, and critical illness in children. Lancet 2009; 374: 605-7.
40. Louie JK, Acosta M, Samuel MCet al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis 2011; 52: 301-12.
41. Webb SA, Pettila V, Seppelt I et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361: 1925-34.
42. Miller RR III, Markewitz BA, Rolfs RT et al. Clinical findings and demographic factors associated with ICU admission in Utah due to novel 2009 influenza A(H1N1) infection. Chest 2010; 137: 752-8.
43. Flint SM, Davis JS, Su JY et al. Disproportionate impact of pandemic (H1N1) 2009 influenza on indigenous people in the top end of Australia's Northern Territory. Med J Aust 2010; 192: 617-22.